Adding the novel drug XEN1101 to current antiseizure regimens significantly decreases seizures in patients with treatment-resistant focal epilepsy and can safely be taken at its highest dose, results ...

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Most participants with newly diagnosed focal episodes achieve seizure freedom; 27% become seizure-free with first antiseizure medications. HealthDay News — Many people with newly diagnosed focal ...

Los Angeles — Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications (ASMs), new research suggested. This is sobering information to pass ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among those deemed “treatment sensitive,” 69.4% ...

Epilepsy is a disorder of the brain that affects the nervous system. Epilepsy causes abnormal electrical activity in the brain, which leads to seizures. There are many types of seizure medication, all ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they, too, may eventually see improvement, if ...